6533b821fe1ef96bd127b773
RESEARCH PRODUCT
Re-irradiation With Carbon Ion Radiotherapy for Pelvic Rectal Cancer Recurrences in Patients Previously Irradiated to the Pelvis
Lorenzo PredaAlfredo MirandolaAlessandro VanoliViviana VitoloAngelica FacoettiAndrea PelosoGiulia RivaSara RonchiE. D’ippolitoFrancesco CucciaMaria BonoraAmelia BarcelliniFrancesca ValvoLorenzo CobianchiRachele PetrucciFrancesca Dal MasAlberto IannalfiMaria Rosaria FioreBarbara Vischionisubject
Re-IrradiationAdultMaleCancer Researchmedicine.medical_specialtyColorectal cancerHeavy Ion RadiotherapyKaplan-Meier EstimateGeneral Biochemistry Genetics and Molecular BiologyPelvisRe-Irradiation03 medical and health sciences0302 clinical medicineSettore MED/36 - Diagnostica per Immagini e RadioterapiamedicineHumansIn patientRectal cancer recurrenceCarbon ion radiotherapy; Rectal cancer recurrence; Reirradiation; Adult; Aged; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence Local; Pelvis; Prognosis; Rectal Neoplasms; Tomography X-Ray Computed; Treatment Outcome; Heavy Ion Radiotherapy; Re-IrradiationTomographyPelvisRecurrent Rectal CancerReirradiationAgedPharmacologyddc:617business.industryRectal NeoplasmsMiddle Agedmedicine.diseasePrognosisMagnetic Resonance ImagingX-Ray Computedmedicine.anatomical_structureNeoplasm RecurrenceTreatment OutcomeLocalCarbon ion radiotherapy030220 oncology & carcinogenesisMetastasis free survivalCarbon Ion RadiotherapyFemaleRadiologyNeoplasm Recurrence LocalbusinessTomography X-Ray ComputedPelvic InfectionResearch ArticleFollow-Up Studiesdescription
Background/Aim: Re-irradiation of locally recurrent rectal cancer poses challenges due to the proximity of critical organs, such as the bowel. This study aimed at evaluating the safety and efficacy of re-irradiation with Carbon Ion Radiotherapy (CIRT) in rectal cancer patients with local recurrence. Patients and Methods: Between 2014 and 2018, 14 patients were treated at the National Center of Oncological Hadrontherapy (CNAO Foundation) with CIRT for locally recurrent rectal cancer. Results: All patients concluded the treatment. No G≥3 acute/late reaction nor pelvic infections were observed. The 1-year and 2-year local control rates were, 78% and 52%, respectively, and relapse occurred close to the bowel in 6 patients. The 1-year and 2-year overall survival rates were 100% and 76.2% each; while the 1-year and 2-year metastasis free survival rates were 64.3% and 43%. Conclusion: CIRT as re-irradiation for locally recurrent rectal cancer emerges as a safe and valid treatment with an acceptable rate of morbidity of surrounding healthy tissue.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2020-05-03 |